Four key stages to our approach:
Proteins, biochemistry, lipid species, cells, DNA, RNA, exosomes, OCT plaque-imaging
Simultaneous multi-port intra-coronary trans-plaque blood sampling
Laminar flow mixing capability to ensure truly representative samples obtained
Diagnostics and patient stratification
Biosignatures of disease
Target and pathway identification
Re-purposed medicines & novel therapeutics
Interrogation, correlation and visualisation of data and disease endotypes
The Liquid Biopsy System in action
Underpinned by its unique site-of-disease sampling capability, we are working with world-leading scientists and clinicians to better map the local biochemical process of CAD and how they vary between individuals and clinical and demographic sub-groups.
Our endotyping platform is powered by holistic, multi-omic patient and disease databases. This in-vivo disease classification will enable the identification of new disease-specific drug targets and pave the way for a new era of precision medicine for millions of patients with CAD.
Endotyping CAD to accelerate a precision medicine approach
The LBS has two components: the Liquid Biopsy Catheter (LBC) and the Blood Collection Module (BCM). The LBC is deployed within the coronary artery where, with the retraction of the outer sheath, it releases mixing baffles that disrupt the biomolecule-rich boundary layer gently facilitating the homogenisation and collection of biomarkers released at sites of disease. Using vacuum pressure, the LBC draws these blood samples into the BCM, which consists of removable tubes that allow storage for subsequent analysis.
The PlaqueTec Liquid Biopsy System™ (LBS™) is a specialised catheter that quickly and reliably collects blood samples containing biomolecules localising at or being released by coronary plaque.
The Liquid Biopsy System
Trans-plaque blood sampling
The LBS enables collection of samples at multiple sites along the length of a target coronary artery, with the upstream sample acting as the reference, so trans-plaque gradients between samples can be assessed.
This gradient approach addresses the inherent issue of variability between individuals when sampling blood and identifies which of the many putative biomarkers are locally elevated at the most critical site of disease.